Australia markets close in 4 hours 51 minutes

    +21.00 (+0.26%)
  • ASX 200

    +18.60 (+0.24%)

    -0.0000 (-0.00%)
  • OIL

    -0.20 (-0.25%)
  • GOLD

    +0.10 (+0.00%)
  • Bitcoin AUD

    -1,258.86 (-1.18%)
  • CMC Crypto 200

    +34.40 (+2.31%)

    +0.0002 (+0.03%)

    -0.0006 (-0.05%)
  • NZX 50

    +69.24 (+0.59%)

    +39.61 (+0.21%)
  • FTSE

    -7.75 (-0.09%)
  • Dow Jones

    +66.22 (+0.17%)
  • DAX

    -42.20 (-0.22%)
  • Hang Seng

    -415.60 (-2.12%)
  • NIKKEI 225

    -297.89 (-0.76%)

Afya Limited (NASDAQ:AFYA) Q4 2023 Earnings Call Transcript

Afya Limited (NASDAQ:AFYA) Q4 2023 Earnings Call Transcript March 14, 2024

Afya Limited beats earnings expectations. Reported EPS is $0.36, expectations were $0.34. AFYA isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good night [sic] everyone and thank you for joining us for Afya's Fourth Quarter and Full Year 2023 Conference Call. Today, I'm here with Afya's CEO, Virgilio Gibbon; and Luis Andre Blanco, our CFO. During this presentation, our executives will make forward-looking statements. Forward-looking statements could be related to future events, future financial operating performance, known and unknown risks, uncertainties and other factors that may cause Afya's actual results to differ materially from those contemplated by these forward-looking statements. Forward-looking statements in this presentation include, but are not limited to, statements related to the business and financial performance, expectations and guidance for future periods or expectations regarding the company's strategic product initiatives, its related benefits and our expectations regarding the market.

These risks include those more fully described in our filings with the Securities and Exchange Commission. The forward-looking statements in this presentation are based on the information available to us as the date hereof. You should not rely on that as predictions of future events, and we disclaim any obligation to update any forward-looking statements, except as required by law. In addition, management may reference non-IFRS measures on this call. These measures are not intended to be considered in insolation or as a substitute of the results prepared in accordance with IFRS. This presentation has reconciled these non-IFRS financial measures to the most directly comparable IFRS financial measures. Let me now turn the call over to Virgilio Gibbon, Afya's CEO.

A doctor in a lab coat looking at a medical education computer screen, symbolizing digital health services.
A doctor in a lab coat looking at a medical education computer screen, symbolizing digital health services.

Virgilio Gibbon: Thank you, Renata, and welcome to our final conference call of 2022 [ph]. We are excited to present another year of exceptional operational and financial performance for Afya. Once again, we have demonstrated the resilience of our business, the successful implementation of our strategy, and the reliability of our business model. In this presentation, I will cover key strategic topics, including our performance highlights, the successful business execution across our three segments, guidance for 2023, and the new goals for 2024. And finally, Luis Blanco will provide an in-depth look at our financial and operational performance. Now turning to page number three, let's begin by highlighting our performance achievements.


Initially, our adjusted net revenue increased by 24%, reaching R$2,874 million, accompanied by a growth of adjusted EBITDA of over 21% year-over-year, reaching R$1,166 million, with a margin of 40.6%. Furthermore, we are pleased to report a record on cash flow generation from operating activities, concluding the year with R$1,088.8 million, reflecting a 24% increase compared to the previous year, with a cash conversion rate of 97%, which is 270 bps better than the previous year. With consistent momentum throughout the year, our adjusted net income reached R$591 million, in 2023, marking over 10% growth year-over-year, with an EPS of R$6.37, a remarkable 12% increase compared to the previous year. This underscores our disciplined capital allocation on buyback programs, M&A, and an efficient capital structure.

Transition to our operational updates for the year, we have expanded to 3,113 operating seats, witnessing an year-over-year increase of over 12%, facilitated by the acquisition of UNIMA and Faculdade de Ciências Médicas de Aboatão in January of 2022 [ph]. In addition, our number of undergrad medical students has reached more than 21,000, representing a 19% growth compared to 2022. Additionally, we are delighted to report significant growth in net revenue for our continuing education segment, which expanded by more than 35% year-on-year, organically reaching a net revenue of R$147 million. Our digital health services revenue marked another great result with a 21% increase compared to 2022, pure organically, reaching a net revenue of R$229 million.

See also 13 Most Undervalued EV Stocks To Buy According To Analysts and 13 Most Undervalued Blue Chip Stocks To Buy According To Analysts.

To continue reading the Q&A session, please click here.